- Home
- GBIO vs EVE Comparison
GBIO vs EVE Comparison
Compare GBIO & EVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- EVE
- Stock Information
- Founded
- GBIO 2016
- EVE 2021
- Country
- GBIO United States
- EVE United States
- Employees
- GBIO N/A
- EVE N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- EVE Blank Checks
- Sector
- GBIO Health Care
- EVE Finance
- Exchange
- GBIO Nasdaq
- EVE Nasdaq
- Market Cap
- GBIO 145.5M
- EVE 159.3M
- IPO Year
- GBIO 2020
- EVE 2021
- Fundamental
- Price
- GBIO $2.50
- EVE $11.00
- Analyst Decision
- GBIO Buy
- EVE
- Analyst Count
- GBIO 4
- EVE 0
- Target Price
- GBIO $7.50
- EVE N/A
- AVG Volume (30 Days)
- GBIO 63.3K
- EVE 12.1K
- Earning Date
- GBIO 08-07-2024
- EVE 01-01-0001
- Dividend Yield
- GBIO N/A
- EVE N/A
- EPS Growth
- GBIO N/A
- EVE 4067.26
- EPS
- GBIO N/A
- EVE 0.24
- Revenue
- GBIO $13,174,000.00
- EVE N/A
- Revenue This Year
- GBIO $99.36
- EVE N/A
- Revenue Next Year
- GBIO N/A
- EVE N/A
- P/E Ratio
- GBIO N/A
- EVE $45.05
- Revenue Growth
- GBIO 1397.05
- EVE N/A
- 52 Week Low
- GBIO $0.86
- EVE $10.63
- 52 Week High
- GBIO $4.65
- EVE $12.03
- Technical
- Relative Strength Index (RSI)
- GBIO 49.32
- EVE 44.51
- Support Level
- GBIO $2.13
- EVE $10.97
- Resistance Level
- GBIO $2.49
- EVE $11.07
- Average True Range (ATR)
- GBIO 0.21
- EVE 0.06
- MACD
- GBIO 0.01
- EVE -0.00
- Stochastic Oscillator
- GBIO 46.91
- EVE 75.51
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
About EVE EVe Mobility Acquisition Corp
EVe Mobility Acquisition Corp is a blank check company.